Biocon Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon announced its Q1 FY26 results with consolidated revenue from operations growing ~15% year-on-year to Rs 39,419 million, driven by an 18% jump in the Biosimilars segment to Rs 24,578 million. However, the Generics segment swung to a loss of Rs 670 million from a profit of Rs 169 million, and consolidated operating margin compressed sharply from 25.25% to 21.02%. Consolidated profit attributable to shareholders fell steeply to Rs 274 million from Rs 4,367 million, largely because the year-ago quarter included a one-time gain of Rs 10,573 million from the sale of Biocon Biologics' India business to Eris Lifesciences. On a standalone basis, the company posted a net loss of Rs 83 million versus a Rs 9 million profit a year ago. The statutory auditor issued an unqualified limited review report on both standalone and consolidated results.
The headline earnings look weak, but the steep year-on-year decline is mostly a base-effect issue from the Eris sale gain in Q1 FY25. Underlying revenue growth and Biosimilars momentum are positives, while the Generics loss and margin compression are near-term concerns. The Rs 45,000 million QIP raised during the quarter strengthens the balance sheet (debt/equity improved to 0.49 from 0.64) and should ease subsidiary BBL's debt burden, supportive for the stock in the medium term.